ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

This article originally appeared here.
Share this content:
ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing
ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

WEDNESDAY, Dec. 7, 2016 (HealthDay News) -- According to a presentation at the annual meeting of the American Society of Hematology, held from Dec. 3 to 6 in San Diego, an artificial red blood cell has been created that can effectively pick up oxygen in the lungs and deliver it to tissues throughout the body.

The artificial blood cell, which is about one-fiftieth the size of a normal red blood cell, is made from purified human hemoglobin proteins that have been coated with a synthetic polymer. The coating was developed by the study's lead researcher, Dipanjan Pan, Ph.D., an assistant professor of bioengineering with the University of Illinois at Urbana-Champaign.

The surface chemistry of the polymer reacts to the pH level of blood as it travels through the body, senior researcher Allan Doctor, M.D., a critical care specialist at the Washington University School of Medicine in St. Louis, told HealthDay. It captures oxygen when blood pH is high, and releases oxygen when blood pH is low. The polymer coating also keeps the hemoglobin from reacting with nitric oxide in the bloodstream, thus preventing dangerous constriction of the blood vessels, he added. And because the polymer coating is "immune silent," the artificial blood can be used in anyone regardless of blood type, Doctor said.

Lab tests involving mice and rats have proven that the artificial red blood cells can effectively deliver oxygen to needy tissues, the researchers reported. "We replaced 70 percent of the mouse's blood volume with the blood substitute," Doctor said. "Those mice were indistinguishable from those who received a transfusion from another mouse."

Several authors disclosed financial ties to KaloCyte, which is developing the artificial blood cell.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »